

# Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury

Paul H. Hayashi, MD, MPH<sup>1</sup> Robert J. Fontana, MD<sup>2</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina

<sup>2</sup>Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan

Address for correspondence Paul H. Hayashi, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina, Burnett-Womack Bldg., Room 8011, Chapel Hill, NC 27599-7584 (e-mail: paul\_hayashi@med.unc.edu).

Semin Liver Dis 2014;34:134–144.

## Abstract

Patients with idiosyncratic drug-induced liver injury (DILI) can pose substantial diagnostic, prognostic, and therapeutic challenges to the practicing gastroenterologist. The presentation of DILI may vary from asymptomatic liver enzyme elevation to acute liver failure. Although most DILI resolves following drug discontinuation, up to 20% of patients progress to chronic DILI further challenging the clinicians diagnostic and management skills. Also, some medications can lead to advanced fibrosis, encephalopathy, and portal hypertension without significant elevation in liver enzymes during exposure. Finally, there are no objective tests to definitively diagnose DILI. Although causality assessment instruments are available, none are widely accepted or used in clinical practice. Therefore, the diagnosis of DILI depends on thorough and accurate history taking, follow-up of the patient's clinical course and excluding more common causes of liver injury. In this review, we discuss the variable clinical presentations, course, and diagnostic methods used to establish a diagnosis and prognosis in DILI.

## Keywords

- ▶ hepatotoxicity
- ▶ diagnostic tools
- ▶ prognosis
- ▶ histology
- ▶ acute
- ▶ chronic

There are increasing reports of drug-induced liver injury (DILI) leading to clinically significant acute and chronic liver disease in both children and adults.<sup>1–4</sup> Drug-induced liver injury remains the leading cause of acute liver failure (ALF) in Western countries and the most common reason for removal of approved medications from the marketplace.<sup>5,6</sup> The lack of objective diagnostic tests, wide range of clinical presentations and idiosyncratic nature of most cases (i.e., independent of drug dose, duration, route of exposure or identifiable host factors), makes DILI a significant challenge for the practicing gastroenterologist. In the last several years, data acquired from several ongoing prospective registries of DILI cases have started to shed more light on the clinical features, diagnosis, and clinical course of DILI.

## Symptoms and Signs of Drug-Induced Liver Injury

The initial symptoms and signs of DILI are often nonspecific (e.g., fatigue, nausea, and abdominal pain). In the U.S. Drug

Induced Liver Injury Network (DILIN) registry of over 1,200 consecutive cases, nausea was present in 60% and abdominal pain in 42% (Robert Fontana, personal communication). The onset of clinical symptoms can be important in determining the latency of a possible DILI episode. Liver-specific symptoms and signs (e.g., pruritus, jaundice, ascites, and encephalopathy) are usually only present in patients with more severe DILI. In the DILIN and Spanish registries, ~ 70% of patients were jaundiced at presentation and 51% had pruritus. Jaundice in the setting of an acute hepatocellular injury, is associated with a mortality of 10%, often referred to as Hy's Law after the late Hy Zimmerman.<sup>1,2,7,8</sup> Ascites and encephalopathy are well-known ominous signs of hepatic failure.<sup>9</sup> Drug-induced liver injury remains the overall leading cause of acute liver failure (ALF) in the U.S. and idiosyncratic DILI is the second leading cause among cases where an etiology is identified.<sup>10</sup> The leading agents causing ALF are antituberculosis agents (isoniazid), antiepileptics (phenytoin, valproate), and antibiotics (ketoconazole, nitrofurantoin), followed by herbal and dietary supplements (HDS).<sup>10,11</sup>

Issue Theme Drug-Induced Liver Injury; Guest Editors, Naga Chalasani, MD, and Paul H. Hayashi, MD, MPH

Copyright © 2014 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0034-1375955>. ISSN 0272-8087.

Drugs and HDS products may also cause subclinical liver injury. For example, isoniazid therapy for latent TB will cause mild serum alanine aminotransferase (ALT) elevation in up to 20 to 30% of treated patients. Many of these will develop tolerance and experience a decline in ALT levels despite continued INH use.<sup>12-14</sup> The heparin compounds can cause asymptomatic serum ALT elevations as well. A recent study in healthy volunteers showed that most will have some elevation in serum ALT levels and many had elevations greater than 3 to 5 times the upper limit of normal.<sup>15</sup> These elevations occur with all the heparin compounds even when delivered subcutaneously and resolve with continued therapy.<sup>16</sup> The combination of human immunodeficiency virus (HIV) antiretrovirals, atazanavir, and ritonavir can also cause self-limited unconjugated hyperbilirubinemia in up to 44% of treated patients that resolves with drug discontinuation.<sup>17</sup>

Immunoallergic features may be a prominent feature in some DILI patients and at least one immunologic feature was present in 23% of the DILIN patients.<sup>2</sup> Certain agents such as allopurinol, sulfamethoxazole/trimethoprim, vancomycin, and phenytoin<sup>18-21</sup> frequently present with prominent immunoallergic features such as rash, fever, serositis, eosinophilia, bone marrow suppression, and multiorgan involvement (DRESS). In general, rechallenge in such cases will lead to a more rapid recurrence presumably due to immunologic memory of T and B cells. Other medications such as nitrofurantoin, minocycline, and  $\alpha$ -methyl dopa may cause an immune-mediated injury that is indistinguishable from sporadic autoimmune hepatitis. Autoimmune markers (antinuclear and antismooth muscle antibodies) may be markedly positive and histology may look identical to autoimmune hepatitis. The latencies can be quite long (months to years) and confidently distinguishing DILI from autoimmune hepatitis (AIH) often depends on resolution with medication discontinuance and lack of need for prolonged immunosuppressive therapy.<sup>22</sup> Biologics including anti-TNF agents used to treat inflammatory bowel disease can also lead to severe acute liver injury with autoimmune hepatitis-like features.<sup>23</sup>

### Atypical Clinical Presentations

Drug-induced liver injury can occasionally present with only modest or no elevations in liver biochemistries. Chronic use of methotrexate is probably the most well-known example. Serum aminotransferase elevations are typically mild, yet a steatotic liver injury with fibrosis can occur over months to years of therapy.<sup>24</sup> The risk of cirrhosis was probably exaggerated in early reports due to confounding from concomitant alcohol consumption as well as underlying nonalcoholic fatty liver disease. Nevertheless, the potential for chronic liver injury in up to 5 to 10% of treated patients is widely accepted and guidelines from both dermatology<sup>25</sup> and rheumatology<sup>26,27</sup> professional societies recommend monitoring of serum aminotransferase levels with periodic liver biopsy depending on the levels, patient risk factors, and cumulative drug exposure.

Hepatotoxicity from the antiepileptic, valproate is noteworthy for its three distinct presentations (**Table 1**).<sup>28,29</sup> It may present acutely with jaundice, anorexia, and encephalopathy.

Oddly, liver enzyme elevations may be modest in comparison to other injuries presenting with such severe hepatic dysfunction. Valproate hepatotoxicity can also present abruptly with a Reye's-like syndrome typically in children. Here again, liver biochemistry abnormalities are often modest and overshadowed by the neurologic complaints of anorexia, lethargy, cerebral edema, and coma. Lastly, valproate can cause a hyperammonemic encephalopathy without overt liver injury.<sup>30</sup> The reasons for this odd array of presentations lie in valproate's mitochondrial toxicity. Microvesicular steatosis is seen on liver biopsy and carnitine depletion is felt to play a role in the pathophysiology. Mutations in the gamma polymerase gene that codes for the predominant DNA polymerase in mitochondria may influence patient susceptibility.<sup>31</sup>

Patients with DILI may also rarely present with noncirrhotic portal hypertension and associated variceal bleeding and/or ascites, but preserved hepatic synthetic function. Nodular regenerative hyperplasia (NRH) may be present on needle biopsy, but other times histology is unrevealing. Several medications including oral contraceptives, antineoplastics, and immunosuppressives have been implicated. Due to the indolent development of portal hypertension from stellate cell stimulation and liver regeneration, latency periods can be long. Azathioprine, which has been associated with NRH, remains a mainstay treatment for inflammatory bowel disease and autoimmune hepatitis. Oxaliplatin is commonly used for stage III colon cancer and has also recently been associated with significant portal hypertension in the absence of overt liver inflammation or synthetic dysfunction.<sup>32,33</sup> Both drugs also have been linked to sinusoidal obstructive syndrome.

Sinusoidal obstructive syndrome (SOD) usually presents more abruptly with evidence of portal hypertension and signs of hepatic dysfunction, but liver biochemistries may be only mildly elevated. Sinusoidal obstructive syndrome is typically associated with myeloablative chemotherapy given for hematologic malignancies, but other chemotherapeutic agents given for other diseases have also been implicated.<sup>34</sup> Sinusoidal obstructive syndrome typically presents with right upper-quadrant pain, weight gain, jaundice, and hepatomegaly of varying severity. Ascites may or may not be present. Although drug latency is usually short (i.e., 20–30 days), the diagnosis can be difficult to confidently establish because these patients are often at risk for other causes of liver injury including opportunistic infections, sepsis, ischemia, and exposure to other hepatotoxic medications including antifungals and antibacterials. Furthermore, it may be difficult to distinguish early graft versus host disease from delayed SOD. Two diagnostic criteria have been published for SOD, but still 10–20% cannot be diagnosed definitely without a biopsy.<sup>35,36</sup>

### Diagnostic Evaluation of Suspected Drug-Induced Liver Injury

Drug-induced liver injury diagnosis depends on obtaining a meticulous history and thoughtful use of diagnostic tests. However, making this effort upfront can save weeks in

**Table 1** Latency and presentation with commonly implicated drugs that may cause liver injury

Antibiotics	Typical latency*	Typical pattern of injury / identifying features
Amoxicillin/clavulanate	1–4 wk	Cholestatic injury, but can be hepatocellular at initial presentation
Isoniazid	1–6 mo	Acute hepatocellular injury similar to acute viral hepatitis
Sulfamethoxazole/trimethoprim	Short to moderate (< 4 wk)	Cholestatic injury, but can be hepatocellular; often with immunoallergic features (e.g., rash, eosinophilia)
Fluoroquinolones	Short (1–14 d)	Equally hepatocellular, cholestatic or mixed
Nitrofurantoin		
Acute form (rare)	Short	Hepatocellular
Chronic form	Moderate to Long (mo–y)	Typically hepatocellular and often identical to autoimmune hepatitis
Minocycline	Moderate to Long	Hepatocellular and often identical to autoimmune hepatitis
Antiepileptics		
Phenytoin	Short to moderate	Hepatocellular, mixed or cholestatic often with immunoallergic features (e.g., rash, eosinophilia)
Carbamazepine	Moderate	Hepatocellular, mixed or cholestatic often with immunoallergic features
Lamictal	Moderate	Hepatocellular often with immunoallergic features
Valproate		
Hyperammonia	Moderate to long	Elevated ammonia, encephalopathy
Hepatocellular	Moderate to long	Hepatocellular
Reye-like syndrome	Short to moderate	Hepatocellular, acidosis; microvesicular steatosis on biopsy
Analgesics		
Nonsteroidal anti-inflammatory agents	Moderate to long	Hepatocellular injury
Immune modulators		
Interferon $\beta$	Moderate to long	Hepatocellular, female predominance
Miscellaneous		
Methotrexate (oral)	Long (> 1 y)	Fatty liver, fibrosis
Allopurinol	Short to moderate	Hepatocellular or mixed. Often with immunoallergic features; granulomas on biopsy
Amiodarone (oral)	Moderate to long	Hepatocellular, mixed or cholestatic; macrovesicular steatosis on biopsy
Androgen-containing steroids	Moderate to long	Cholestatic. Can present with peliosis hepatitis, nodular regenerative hyperplasia or hepatocellular carcinoma
Inhaled anesthetics	Short	Hepatocellular. May have immunoallergic features $\pm$ fever.
Gastrointestinal Medications		
Interferon alpha	Moderate	Hepatocellular, autoimmune hepatitis-like
Anti-tumor necrosis factor agents	Moderate to long	Hepatocellular. Can have autoimmune hepatitis features
Azathioprine	Moderate to long	Cholestatic or hepatocellular, but can present with portal hypertension (veno-occlusive disease, nodular regenerative hyperplasia)
Macrolides	Short	Hepatocellular, but can be cholestatic
Sulfasalazine	Short to moderate	Mixed, hepatocellular, or cholestatic; often with immunoallergic features
Proton pump inhibitors	Short	Hepatocellular; very rare

\*Short = 3–30 days, Moderate = 30–90 days, Long &gt; 90 days unless otherwise specified.

diagnostic evaluation, decrease morbidity, and avoid unnecessary tests. Overall, the assessment focuses on four major areas: (1) timing (exposure or latency; recovery or dechallenge), (2) pattern of liver biochemistries at presentation, (3) hepatotoxicity profile of suspect agent, and (4) exclusion of competing causes. Judicious use of blood tests and liver imaging are necessary, but liver biopsy, while often helpful, is not mandatory. Drug-induced liver injury assessment has been organized into diagnostic scoring systems<sup>37–39</sup> that are useful in organizing data into a categorical framework. However, they are not widely used in practice due to lack of proven reliability and accuracy. Others have published more complete lists of necessary clinical data that can serve as a checklist for the clinician (►Table 2).<sup>40,41</sup>

The importance of getting accurate timing of medication start and stop dates (exposure), onset of symptoms, or liver

biochemistry abnormalities (latency) and liver recovery (dechallenge) cannot be overemphasized. Such timing information is the initial parameter for all diagnostic algorithms<sup>37,39</sup> because inaccurate exposure data will undermine any final diagnosis. For prescription drugs, contacting the patient's pharmacy can be invaluable in defining exposure and completeness of all medications taken.<sup>42</sup> Nowadays, getting a complete medication list also includes asking patients about herbal and dietary supplement (HDS) use; supplements are taken by over 50% of the U.S. population.<sup>43</sup> Recent data suggest HDS hepatotoxicity attributed to body building supplements, weight loss products, and other formulations containing various amounts of potentially hepatotoxic ingredients (e.g., catechins) is on the rise in the United States.<sup>44,45</sup> Determining onset of signs or symptoms is particularly challenging because a patient's memory can be

**Table 2** Minimum elements of a diagnostic evaluation in patients with suspected drug-induced liver injury

Element	Comments
Gender	Pertinent for some competing disorders (e.g., PBC)
Age	Pertinent for some competing disorders (e.g., HEV)
Race/ethnicity	Pertinent for some competing disorders (e.g., sarcoidosis, sickle cell-related liver injury, oriental sclerosing cholangitis)
Indication for suspect drug or HDS use	May have underlying liver disease (hypoglycemic agents in diabetics, weight-loss products in obese, etc.)
Concomitant diseases	Particularly pertinent disorders may include sepsis, heart failure, hypotension episodes, recent general anesthesia, parenteral nutrition, and cancer
Presence of rechallenge	Give timing of rechallenge if done
History of other drug reactions	Certain cross reactivities may exist (e.g., antiepileptics)
History of other liver disorders	Chronic viral hepatitis, NAFLD, hemochromatosis, alcoholic liver disease, PSC, PBC, liver cancer
History of alcohol use	Past versus present; estimated grams per day; sporadic versus binge drinking versus regular (daily or weekly)
Exposure time	Start and stop dates or total number of days, weeks, or months taken.
Symptoms & signs	Presence or absence, time of onset, type (fatigue, weakness, abdominal pain, nausea, dark urine, icterus, jaundice, pruritus, fever, rash)
Physical findings	Fever, rash, hepatic tenderness, signs of chronic liver disease
Medications & HDS products	Complete list of medications or HDS products with particular attention to those started in the previous 3–6 mo
Laboratory results	Day of first abnormal liver biochemistry; liver biochemistries, eosinophil counts at presentation
Viral hepatitis serologies	Anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HCV, HCV RNA
Autoimmune hepatitis serologies	ANA, antismooth muscle antibody, IgG level
Imaging	US ± Doppler, CT, or MRI ± MRCP
Histology if available	Timing of biopsy in relation to enzyme elevation and drug-induced liver injury onset
Washout (dechallenge) data	Follow-up liver biochemistries over 3–6 mo after drug discontinuation
Clinical outcome	Resolution versus chronicity, transplant, death, and timing of each

Abbreviations: ANA, antinuclear antibody; CT, computerized tomography; HAV, hepatitis A virus; HBc, hepatitis B core antigen; HBs, hepatitis B surface antigen; HCV, hepatitis C virus; HDS, herbal or dietary supplement; HEV, hepatitis E virus; Ig, immunoglobulin; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; RNA, ribonucleic acid; US, ultrasound.

Source: Modified from Agarwal VK et al.<sup>40</sup>

vague and subject to recall bias. Interviewing family and friends may be necessary, and recall cues used in epidemiology research can be helpful.<sup>46,47</sup>

The pattern of liver biochemistry elevations at presentation is second only to a good history in diagnostic importance. Elevations are often categorized by the *R* value ( $R = [\text{ALT value}/\text{ALT upper limit of normal}] \div [\text{alkaline phosphatase (AP) value}/\text{AP upper limit of normal}]$ ).<sup>48</sup> *R* values of  $> 5$  are considered hepatocellular,  $< 2$  cholestatic, and 2–5 mixed. These cutoffs are somewhat arbitrary and *R* values can also change as the injury progresses, particularly from hepatocellular to cholestatic pattern over time.<sup>38</sup> Nevertheless, they serve as a useful way to focus a diagnostic evaluation on particular hepatotoxic agents and competing diagnoses.

### Likelihood of Liver Injury from a Drug

Knowledge of the likelihood that a given drug can cause hepatotoxicity is important when assessing a patient with possible DILI. Overall, antibiotics and antiepileptics are most commonly reported accounting for up to 60% of DILI.<sup>1</sup> Therefore, the appearance of either of these two classes of agents on a medication list should heighten one's suspicion for DILI. On the other hand, antihypertensive and diabetic medications are less commonly reported.<sup>1</sup> Certain offenders have signature presentations (e.g., amoxicillin-clavulanate, isoniazid, phenytoin), and ▶ **Table 1** lists the most notorious as well as commonly prescribed agents including those often prescribed by gastroenterologists. For example, isoniazid injury is virtually always hepatocellular and fluoroquinolone injury typically has a very short latency. Idiosyncratic DILI inherently offers few generalizations across all medications, but a recent study suggests drugs given in daily doses exceeding 100 mg/d and those that are more lipophilic may be more likely to cause hepatotoxicity.<sup>49,50</sup>

Staying abreast of less well-known or newly reported agents associated with DILI is more difficult with the Food and Drug Administration (FDA) having approved an average of 90 drugs per year from 2007–2011 alone.<sup>51</sup> Published DILI cases are spread across subspecialty, toxicology, pharmacology, and gastroenterology journals. Recently, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine (NLM) launched *LiverTox* (<http://www.livertox.nih.gov/>), a free online resource that is updated on a regular basis.<sup>52,53</sup> Over 650 medications are included on the website and this number continues to grow. Each medication is presented in a concise and clinically useful manner. References are robust and linked to the NLM. This website has quickly become a mainstay tool to the clinician and researcher alike with over 30,000 visits per month. There are plans to expand the *LiverTox* website to include all marketed prescription drugs and some HDS products, as well as provide a computerized causality assessment instrument to assist in DILI diagnosis.

### Competing Causes of Liver Injury

Searching for more common competing diagnoses of liver injury based upon the laboratory profile at presentation is also important. Hepatocellular injuries prompt suspicions of

viral hepatitis, ischemia, and autoimmune hepatitis. A detailed alcohol history is critical when the transaminase pattern (modest elevation; aspartate aminotransferase [AST]  $> 2 \times$  ALT) is consistent with alcoholic hepatitis. A rapid rise and fall of serum aminotransaminase levels are hallmarks for ischemic injury. Autoimmune hepatitis (AIH) is often one of the more difficult competing diagnosis to eliminate because like DILI there is no single objective diagnostic test for AIH.<sup>54</sup> Budd-Chiari syndrome can also present with acute hepatocellular injury and should be pursued with appropriate imaging studies (e.g., Doppler ultrasound, computed tomography or magnetic resonance imaging).

Such diagnostic evaluation of hepatocellular enzyme elevation is well known to the gastroenterologist. However, there are some noteworthy diagnoses that masquerade as DILI. Even though 10,000 new infections occur in the United States annually, acute hepatitis C is often overlooked because gastroenterologists are more accustomed to seeing the indolent chronic phase of infection, and diagnostic test results are variable in acute infection. Very early in infection, hepatitis C virus (HCV) antibody can be negative, and HCV RNA testing may be necessary. Detectable HCV RNA without antibody is consistent with acute infection. Seroconversion in the following 4 to 12 weeks with or without loss of HCV RNA would be strong evidence for acute infection, particularly if a recent risk factor were identified. Ultimately, repeat history taking for hepatitis C risk factors and retesting of HCV antibody and RNA in 4 to 12 weeks should be done, but are often forgotten. Pursuing the diagnosis of acute hepatitis C takes on added importance as we enter an era of more tolerable and curative therapies.

Cytomegalovirus (CMV) and Epstein Barr virus (EBV) hepatitis are uncommon in the immunocompetent host,<sup>55</sup> but hepatocellular liver enzyme elevation in systemic CMV infection is often seen.<sup>56,57</sup> Herpes simplex virus (HSV) hepatitis patients are frequently younger, with high fever and can have quite severe or fatal liver injury.<sup>58</sup> Immunocompromised patients are more at risk, but cases in the immunocompetent are described.<sup>59</sup> All three have acute serologic panels as well as polymerase chain reaction (PCR) testing available. No studies have looked systematically at how often suspected DILI cases are actually HSV, EBV, or CMV hepatitis. Therefore, these viral infections should be considered in cases with suggestive symptoms (e.g., fever, lymphadenopathy, splenomegaly, herpetic lesions). For all viral infections, antibody testing may be less sensitive in the immunocompromised host and nucleic acid testing should be done.

Hepatitis E is uncommon in North America and Western Europe, but has been documented to masquerade as DILI. Dalton and colleagues suggested a 12% acute hepatitis E rate in 47 cases thought to be DILI from the United Kingdom and New Zealand based on hepatitis E virus (HEV) IgG and IgM serologies.<sup>60</sup> The DILIN retrospectively searched its registry for evidence of acute hepatitis E in 318 cases. All nine cases with positive HEV serologies were tested for HEV RNA, and re-evaluated by the DILIN group for likelihood of DILI versus HEV. Seven (2%) were felt to be more likely acute hepatitis E

than DILI after re-evaluation.<sup>61</sup> These cases of unsuspected acute HEV were predominantly in men over 50 years of age in both studies. Although the zoonotic spread of HEV from pigs, boar, and deer is postulated, a strong epidemiologic link is lacking.<sup>62</sup> Outbreaks associated with travel to endemic areas (e.g., Southeast Asia, Asian subcontinent, Africa, and Mexico) are seen. Currently, tests for anti-HEV IgG and IgM levels are commercially available, but not FDA approved. In addition, testing for HEV RNA by PCR is not available in the United States. Therefore, routinely testing for anti-HEV cannot be recommended at this time, but may be considered if there is a potential exposure history (e.g., recent travel to endemic regions).

Though rare, Wilson disease is often considered as a competing diagnosis during the workup for acute hepatocellular injury particularly when acute liver failure (ALF) is present. Diagnostic guidelines for Wilson disease are available,<sup>63</sup> but if ALF is present, then the ratios of AP:bilirubin < 4 and AST:ALT > 2.2 have shown better diagnostic accuracy.<sup>64</sup>

Cholestatic injuries prompt concerns for biliary problems such as choledocholithiasis, pancreaticobiliary tumors, strictures, and infiltrating cancer. Evaluation for these disorders is commonplace for the gastroenterologist. Guidelines for the role of endoscopic retrograde cholangiography (ERC) and endoscopic ultrasound (EUS) in the evaluation and treatment of choledocholithiasis were published in 2010 and are driven by serum bilirubin levels > 1.8 to 4.0 mg/dL and ultrasound imaging.<sup>65</sup> However, these guidelines are specifically for patients with “symptomatic cholelithiasis.” In contrast to stone obstruction, cholestatic DILI is often more insidious in onset with pruritus, fatigue, nonspecific abdominal complaints, or no symptoms at all. Therefore, caution should be taken in applying the American Society for Gastrointestinal Endoscopy (ASGE) algorithm for early ERC in the absence of

clinical symptoms or ductal dilation on imaging, even when the bilirubin is > 4 mg/dL, a “very strong” predictor for bile duct stone when typical cholelithiasis symptoms are present. Indeed, the absence of duct dilation on ultrasound carries a 95% negative predictive value for choledocholithiasis especially with a bilirubin > 5 to 6 mg/dL.<sup>66</sup> First-time presentations of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are also familiar to the gastroenterologist and diagnostic guidelines are available.<sup>67,68</sup>

The differential and diagnostic evaluation of patients with an acute “mixed” liver injury pattern is broader. Such mixed pattern liver biochemistries can be particularly challenging because transition from predominantly hepatocellular to cholestatic injury can occur. A patient may present late with cholestatic enzyme elevation and the prior elevation of transaminases was missed. Here the latency between symptom onset and first testing of liver enzymes may be a helpful clue.

### Liver Biopsy

A diagnosis of DILI does not require a liver biopsy, but a biopsy can be helpful in confirming a clinical suspicion of DILI and helping to exclude competing etiologies.<sup>1</sup> Some histologic findings may be quite suggestive of possible DILI (→ **Table 3**) and textbook descriptions of these are available.<sup>69,70</sup> Kleiner et al recently catalogued the histologic findings from 249 consecutive DILIN cases and found most (83%) fall into six major categories of injury (acute hepatitis, chronic hepatitis, acute cholestasis, chronic cholestasis, zonal necrosis, and cholestatic hepatitis).<sup>71</sup> Interestingly, the correlation with the *R* value was not very strong with significant overlap of *R* values across the histologic categories. However, certain histologic findings such as necrosis, fibrosis, and microvesicular steatosis were associated with worse outcomes, whereas granulomas and

**Table 3** Clinical phenotypes of drug-induced liver injury, histologic features, and exemplary agents

Phenotype	Histological features	Example agents
Acute fatty liver with lactic acidosis	Microvesicular hepatic steatosis ± other tissue involvement	Didanosine, Fialuridine, Valproate
Acute hepatic necrosis	Collapse and necrosis of liver parenchyma	Isoniazid Niacin
Autoimmune-like hepatitis	Plasma cells & interface hepatitis with detectable autoantibodies	Nitrofurantoin, Minocycline
Bland cholestasis	Balloon hepatocytes with minimal inflammation	Anabolic steroids
Cholestatic hepatitis	Balloon hepatocytes with inflammation, predominance of serum alkaline phosphate elevation (phenytoin, amoxicillin-clavulanate)	Phenytoin, Amoxicillin-clavulanate
Fibrosis/ cirrhosis	Hepatic collagenization with minimal inflammation	Methotrexate, Amiodarone
Immunoallergic hepatitis	Eosinophilic infiltrate	Trimethoprim-sulfamethoxazole
Nodular regeneration	Micro- or macroscopic liver nodules	Azathioprine, Oxaliplatin
Nonalcoholic fatty liver	Macro- and microsteatosis, hepatocyte ballooning and periportal inflammation	Tamoxifen
Sinusoidal obstruction syndrome	Inflammation with obliteration of central veins	Busulfan
Vanishing bile duct syndrome	Paucity of interlobular bile ducts	Sulfonamides, Beta-lactams

eosinophilic infiltrates were associated with better outcomes as suggested in prior studies.<sup>71-73</sup>

A biopsy may be mandatory when autoimmune hepatitis (AIH) is a strong competing possibility because diagnostic criteria for AIH include histology.<sup>74</sup> Commitment to immunosuppressive therapy for AIH is often long term and carries risks and side effects.<sup>75,76</sup> In general, persistence of liver biochemistry abnormalities also warrants a liver biopsy because the majority of DILI cases show improvement in liver biochemistries after drug discontinuation. Therefore, persistence of biochemical abnormalities strengthens the possibility of a non-DILI diagnosis that may be elucidated by a biopsy. The decision on when to obtain a liver biopsy is more art than science. One algorithm considers lack of a 50% drop in the difference between ALT peak and upper limit of normal (ULN) 30 days after stopping the suspected agent as weakening a DILI diagnosis significantly.<sup>37</sup> Another puts the cutoff at 60 days.<sup>39</sup> For cholestatic liver injury, a lack of significant drop in AP or bilirubin levels (> 50% drop in peak-ULN or drop to < twice ULN) at 180 days is considered significant. There are no prospective studies examining the yield of biopsy based on these cutoffs. However, considering a biopsy at 60 days for hepatocellular and 180 days for cholestatic enzyme patterns is reasonable. Earlier biopsy may be justified for continued rise in liver biochemistries particularly when any signs of liver failure arise.

Occasionally, a liver biopsy may be necessary for continued use or contemplated rechallenge with an implicated medication such as a chemotherapeutic drug for advanced malignancy. Guidelines for when to obtain a liver biopsy with chronic methotrexate use are published.<sup>25,26</sup> The Roenigk Classification System is the recognized histologic grading system for methotrexate injury.<sup>77</sup>

### Diagnostic Instruments: Roussel Uclaf Causality Assessment Model

There are two DILI specific scoring diagnostic algorithms,<sup>37,39</sup> but only the Roussel Uclaf Causality Assessment Model (RUCAM) has found traction clinically. The RUCAM was intended for use at the bedside or in clinic, and yields a summed score from -10 to 14, higher scores indicating higher likelihood of DILI.<sup>37</sup> Scores are grouped into likelihood levels of “excluded” (score ≤ 0), “unlikely” (1-2), “possible” (3-5), “probable” (6-8), and “highly probable” (> 8). This scoring system is divided into hepatocellular injuries and cholestatic or mixed injuries. Points are given or taken away based on timing, dechallenge, risk factors for DILI, competing medications, competing diagnoses, and rechallenge information (–Table 4). Although simple in concept, ambiguity on how to score certain sections hinders its use. Alcohol use is a risk factor, but not clearly defined. Points are given to a “known hepatotoxin,” but precise definition of such is unclear. These areas of ambiguity probably contribute to RUCAM’s suboptimal retest reliability (reliability coefficient of 0.51, upper 95% confidence limit 0.76).<sup>78</sup>

Validation is difficult without a gold standard for diagnosing DILI, but was attempted using rechallenge and competing hepatotoxin cases as positive and negative controls, respec-

tively.<sup>38</sup> But rechallenge and competing agents are part of the RUCAM algorithm itself hindering the validation analysis. The RUCAM has been compared with the DILIN expert opinion process.<sup>79</sup> Three DILIN hepatologists, using a set protocol, come to a consensus of DILI likelihood.<sup>80</sup> One of five categories similar to the RUCAM is assigned. RUCAM and DILIN concordance across the five categories was modest by Spearman’s coefficient (0.42,  $p < 0.05$ ), but agreement for discerning at least “probable” versus “possible” was 69% with positive (PPV) and negative (NPV) predictive values of 95% and 23%, respectively. If a clinician were merely interested in whether DILI was at least “possible,” the RUCAM agreed with expert opinion 94% of the time with PPV and NPV of 98% and 37%, respectively. Hence, the RUCAM did well in identifying the possibility of DILI, but it could not rule it out.

Although the RUCAM is not a standalone diagnostic instrument, it can be an adjunct to expert opinion. Perhaps its greatest utility is in providing a framework upon which the clinician can organize history taking and tests. It reminds the clinician of the important areas of a DILI history and requires precision on exposure times and latency.<sup>81</sup>

### Natural History

The low incidence and heterogeneity of DILI makes research into its natural history difficult, but large registries and population-based studies are beginning to clarify this issue. In Iceland, the crude overall annual incidence of idiosyncratic DILI was 19.1 case per 100,000 population, which is similar to the rate reported previously in northern France.<sup>3,4</sup> Three registries from Sweden, Spain, and the United States totaling over 1,500 patients reported 6 to 9% having a severe outcome of death or need for liver transplantation within 6 months.<sup>1,2,8</sup> Risk of such early adverse outcome was highest in those with acute hepatocellular injury (7-13%) and lowest with a mixed pattern (2%). However, within these overall severe outcome rates there was wide variation between drugs. In the Swedish registry, both isoniazid and halothane cases of hepatocellular injury had 40% rates of death or transplantation, whereas no such severe outcomes were seen with erythromycin.<sup>8</sup> Across all three studies, elevated bilirubin at presentation was associated with early severe outcome. Therefore, patients presenting or developing jaundice early in their liver injury deserve close follow-up and perhaps early consultation with a transplant center, particularly if the injury pattern is hepatocellular.

For those that do not have an early severe outcome, the course is less clear although most patients are expected to have a full recovery. Indeed, DILI has typically been considered an outcome of extremes from early mortality or need for transplantation on one end and complete recovery on the other. However, even as early as 1999, a study of just 33 patients suggested that chronic damage on biopsy may occur during prolonged follow-up.<sup>82</sup> Case reports of vanishing bile duct syndrome after a DILI episode are also reported. More recent registry data suggest chronic liver injury does occur, but the reported rate is highly dependent on how it is defined. At this point there are no accepted definitions for “chronic

**Table 4** Roussel Uclaf causality assessment model (RUCAM) causality assessment method<sup>37</sup>

Criteria	RUCAM					
	Hepatocellular			Cholestatic or mixed		
Enzyme pattern	Initial exposure	Subsequent exposure	Pts	Initial exposure	Subsequent exposure	Pts
Exposure	Initial exposure	Subsequent exposure	Pts	Initial exposure	Subsequent exposure	Pts
Timing from	5–90 days	1–15 days	+2	5–90 days	1–90 days	+2
Drug start	< 5, > 90 days	>15 days	+1	< 5, > 90 days	> 90 days	+1
Drug stop	≤ 15 days	≤ 15 days	+1	≤ 30 days	≤ 30 days	+1
Course	Difference between peak ALT and upper limit normal (ULN) value			Difference between peak AP (or bili) and upper limit normal (ULN)		
After drug stop	Decrease ≥50% in 8 days		+3	Decrease ≥50% in 180 days		+2
	Decrease ≥50% in 30 days		+2	Decrease < 50% in 180 days		+1
	Decrease ≥50% in > 30 days		0	Persistence or increase or no information		0
	Decrease < 50% in >30 days		–2			
Risk factor	Ethanol: yes		+1	Ethanol or pregnancy: yes		+1
	Ethanol: no		0	Ethanol or pregnancy: no		0
Age	≥ 55		+1	≥ 55		+1
	< 55		0	< 55		0
Other drugs	None or no information		0	None or no information		0
	Drug with suggestive timing		–1	Drug with suggestive timing		–1
	Known hepatotoxin w/ suggestive timing		–2	Known hepatotoxin w/ suggestive timing		–2
	Drug w/ other evidence for a role (e.g., + rechallenge)		–3	Drug w/ other evidence for a role (e.g., + rechallenge)		–3
Competing causes	All Group I <sup>a</sup> & II <sup>b</sup> ruled out		+2	All Group I <sup>a</sup> & II <sup>b</sup> ruled out		+2
	All of Group I ruled out		+1	All of Group I ruled out		+1
	4–5 of Group I ruled out		0	4–5 of Group I ruled out		0
	<4 of Group I ruled out		–2	<4 of Group I ruled out		–2
	Nondrug cause highly probable		–3	Nondrug cause highly probable		–3
Previous information	Reaction in product label		+2	Reaction in product label		+2
	Reaction published; no label		+1	Reaction published; no label		+1
	Reaction unknown		0	Reaction unknown		0
Rechallenge	Positive		+3	Positive		+3
	Compatible		+1	Compatible		+1
	Negative		–2	Negative		–2
	Not done or not interpretable		0	Not done or not interpretable		0

<sup>a</sup>Group I, HAV, HBV, HCV (acute), biliary obstruction, alcoholism, recent hypotension (shock liver).

<sup>b</sup>Group II, CMV, EBV, herpes virus infection.

DILI,” hence the literature in this area is unclear but evolving. In the Sweden registry, 685 patients surviving the first few months after their DILI episode were linked to their national Cause of Death Registry and Hospital Discharge Registry.<sup>83</sup> Follow-up spanned a remarkable median of 11 years (range 3–23). Twenty-three patients (3.4%) were diagnosed with liver disease during a hospitalization or at death, and medical charts reviewed. Of these 23, perhaps 10 (1.4%) had chronic DILI based on chart review indicating no other obvious etiology for their liver disorder. Such criteria based on hospitalization and/or death registration will obviously underesti-

mate the rate by excluding those with less severe course and followed in an outpatient setting.

When chronic DILI is defined more broadly as persistent elevations in liver enzymes, the rate is expectedly higher. In the Spanish registry, chronic DILI was defined as persistently elevated liver biochemistries at 3 months post-DILI for hepatocellular and 6 months for cholestatic or mixed injuries. Here, the overall rate of chronicity was 5.7%. In the U.S. DILIN registry, 18% had persistent elevations at 6 months including all patterns of injury.<sup>84</sup> The clinical and histologic outcome of such patients remains unclear. Moreover, subsequent



development of non-DILI liver disease such nonalcoholic fatty liver disease and prolonged resolution of biochemistries beyond 6 months will need to be considered moving forward. Nevertheless, data suggest chronic DILI whether by immune-mediated injury, vanishing bile ducts, or some other pathophysiology, does exist and may portend future liver-related problems for some.

Thus, the natural history of DILI is dominated by complete recovery for most, but roughly 10% may not survive the initial injury or may require liver transplantation. Another 5 to 10% may be at risk for chronic injury and perhaps long-term morbidity and mortality. The role of clinical cofactors (e.g., NAFLD) and comorbidities (e.g., diabetes) in the risk of developing chronic DILI requires further investigation. Clearly, heterogeneity in hepatotoxic agents and host susceptibility factors play important roles in both early severe outcome and chronic injury. For now, the clinician should be aware of the medications, signs, and symptoms indicating increased risk of early severe outcome. And for the majority of patients surviving the initial injury, the clinician must remember that some may not fully resolve and deserve follow-up.

## Conclusion

The clinical manifestations, diagnosis, and natural history of idiosyncratic DILI remain a challenge for the busy gastroenterologist. Despite its low incidence in the general population,<sup>3,4</sup> DILI remains a common request for gastroenterology consultation both in the inpatient and outpatient setting. Without objective diagnostic tests, clinicians must rely heavily on history taking skills, awareness of the hepatotoxicity risk for various agents, in-depth knowledge of clinical presentation, and evaluation for competing etiologies. Occasionally, DILI may be severe or life-threatening, and risks factors for such must be recognized quickly to provide appropriate care. Thereafter, a minimum of 6 months follow-up to assess for possible chronic injury is necessary. All this takes time, which can be at a premium for the busy clinician. Better diagnostic tools and epidemiologic data will make DILI identification and care easier in the future. For now, the clinician may want to keep the RUCAM (►Table 4)<sup>37</sup> or a clinical checklist (►Table 2)<sup>40</sup> close at hand and refer to the *LiverTox* website for guidance on particular agents.

## References

- Chalasan N, Fontana RJ, Bonkovsky HL, et al; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. *Gastroenterology* 2008;135(6):1924–1934, e1–e4
- Andrade RJ, Lucena MI, Fernández MC, et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 2005;129(2):512–521
- Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology* 2013;144(7):1419–1425, e1–e3, quiz e19–e20
- Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. *Hepatology* 2002;36(2):451–455
- Ostapowicz G, Fontana RJ, Schiødt FV, et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002;137(12):947–954
- Watkins PB. Drug safety sciences and the bottleneck in drug development. *Clin Pharmacol Ther* 2011;89(6):788–790
- Temple R. Hy's law: predicting serious hepatotoxicity. *Pharmacoeconom Drug Saf* 2006;15(4):241–243
- Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005;42(2):481–489
- Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. *Hepatology* 2005;41(5):1179–1197
- Lee WM. Drug-induced acute liver failure. *Clin Liver Dis* 2013;17(4):575–586, viii
- Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. *Liver Transpl* 2009;15(7):719–729
- Danielides IC, Constantoulakis M, Daikos GK. Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. *Am J Gastroenterol* 1983;78(6):378–380
- LiverTox. Isoniazid. Available at: <http://livertox.nlm.nih.gov/Isoniazid.htm>. Accessed June 6, 2013
- Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. *Gastroenterology* 1975;69(2):289–302
- Harrill AH, Roach J, Fier I, et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. *Clin Pharmacol Ther* 2012;92(2):214–220
- LiverTox. Heparins. Available at: <http://livertox.nlm.nih.gov/Heparin.htm>. Accessed October 4, 2013
- McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. *AIDS Patient Care STDS* 2012;26(5):259–264
- Grant L, Lee WL, Rockey DC. Trimethoprim/Sulfamethoxazole hepatotoxicity: Analysis of 31 cases. *Hepatology* 2013; 58(4, Suppl)382A
- Blumenthal KG, Patil SU, Long AA. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. *Allergy Asthma Proc* 2012;33(2):165–171
- Fleming P, Marik PE. The DRESS syndrome: the great clinical mimicker. *Pharmacotherapy* 2011;31(3):332
- Björnsson E. Hepatotoxicity associated with antiepileptic drugs. *Acta Neurol Scand* 2008;118(5):281–290
- Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. *Hepatology* 2010;51(6):2040–2048
- Ghabril M, Bonkovsky HL, Kum C, et al; US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor- $\alpha$  antagonists: analysis of thirty-four cases. *Clin Gastroenterol Hepatol* 2013;11(5):558, e3
- Zimmerman HJ. Oncotherapeutic and immunosuppressive agents. In: Zimmerman HJ. *Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:681–687
- Kalb RE, Strober B, Weinstein G, Leibold M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol* 2009;60(5):824–837
- Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying

- antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008;59(6):762–784
- 27 Kremer JM, Alarcón GS, Lightfoot RW Jr, et al; American College of Rheumatology. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. *Arthritis Rheum* 1994; 37(3):316–328
  - 28 LiverTox. Valproate. Available at: <http://livertox.nlm.nih.gov/Valproate.htm>. Accessed November 5, 2013
  - 29 Zimmerman HJ. Psychotropic and anticonvulsant agents. In: Zimmerman HJ. *Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:504–508
  - 30 Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. *Int Clin Psychopharmacol* 2007;22(6):330–337
  - 31 Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. *Epilepsia* 2008;49(6): 1038–1045
  - 32 Angitapalli R, Litwin AM, Kumar PR, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. *Oncology* 2009;76(5):363–368
  - 33 Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. *Clin Colorectal Cancer* 2009;8(4): 225–230
  - 34 DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. *Hepatology* 2009;49(5):1729–1764
  - 35 McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. *Ann Intern Med* 1993;118(4): 255–267
  - 36 Jones RJ, Lee KS, Beschoner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. *Transplantation* 1987;44(6):778–783
  - 37 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* 1993;46(11):1323–1330
  - 38 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. *J Clin Epidemiol* 1993;46(11):1331–1336
  - 39 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. *Hepatology* 1997;26(3):664–669
  - 40 Agarwal VK, McHutchison JG, Hoofnagle JH; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. *Clin Gastroenterol Hepatol* 2010;8(5): 463–470
  - 41 Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. *Hepatology* 2010;52(2): 730–742
  - 42 Barritt AS IV, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. *Clin Gastroenterol Hepatol* 2010;8(7):635–637
  - 43 Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003–2006. *J Nutr* 2011;141(2):261–266
  - 44 Navarro VJ, Barnhart HX, Bonkovsky HL, et al. The rising burden of herbal and dietary supplement induced hepatotoxicity in the U.S. *Hepatology* 2013;58(4, suppl):264A
  - 45 Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. *Dig Dis Sci* 2013;58(9):2682–2690
  - 46 Means B, Swan GE, Jobe JB, Esposito JL. An alternative approach to obtaining personal history data. In: Biemeer PP, Groves RM, Lyberg LE, Mathiowetz NA, Sudman S, eds. *Measurement of Errors in Surveys*. New York: John Wiley and Sons; 1991:167–183
  - 47 Friedenreich CM. Improving long-term recall in epidemiologic studies. *Epidemiology* 1994;5(1):1–4
  - 48 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. *J Hepatol* 1990;11(2): 272–276
  - 49 Lammert C, Einarsson S, Saha C, Niklasson A, Björnsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. *Hepatology* 2008;47(6):2003–2009
  - 50 Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. *Hepatology* 2013;58(1):388–396
  - 51 Food and Drug Administration. Summary of NDA Approvals & Receipts, 1938 to the present. Available at: <http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm>. Accessed March 31, 2013
  - 52 National Library of Medicine. LiverTox. Available at: <http://www.LiverTox.nih.gov>. Accessed March 31, 2013
  - 53 Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. *Hepatology* 2013;57(3):873–874
  - 54 Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. *Hepatology* 2009;50(2):538–545
  - 55 Fernández-Ruiz M, Muñoz-Codoceo C, López-Medrano F, et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. *Intern Med* 2008;47(22):1963–1966
  - 56 Cohen JL, Corey GR. Cytomegalovirus infection in the normal host. *Medicine (Baltimore)* 1985;64(2):100–114
  - 57 Gupta E, Bhatia V, Choudhary A, Rastogi A, Gupta NL. Epstein-Barr virus associated acute hepatitis with cross-reacting antibodies to other herpes viruses in immunocompetent patients: report of two cases. *J Med Virol* 2013;85(3):519–523
  - 58 Riviere Marcelin J, Jones JM, Costello BA. 41-year-old woman with fever, neutropenia, and elevated transaminase levels. *Mayo Clin Proc* 2013;88(1):113–116
  - 59 Ichai P, Roque Afonso AM, Sebah M, et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. *Liver Transpl* 2005;11(12):1550–1555
  - 60 Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. *Aliment Pharmacol Ther* 2007;26(10):1429–1435
  - 61 Davern TJ, Chalasani N, Fontana RJ, et al; Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. *Gastroenterology* 2011;141(5):1665–1672, e1–e9
  - 62 Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. *N Engl J Med* 2012;367(13):1237–1244
  - 63 European Association for Study of Liver. *EASL Clinical Practice Guidelines: Wilson's disease*. *J Hepatol* 2012;56(3):671–685
  - 64 Dowling D. Screening for Wilson's disease in acute liver failure: a comparison of currently available diagnostic tests. *Hepatology* 2009;50(1):329
  - 65 Maple JT, Ben-Menachem T, Anderson MA, et al; ASGE Standards of Practice Committee. The role of endoscopy in the evaluation of suspected choledocholithiasis. *Gastrointest Endosc* 2010;71(1): 1–9
  - 66 Yang MH, Chen TH, Wang SE, et al. Biochemical predictors for absence of common bile duct stones in patients undergoing laparoscopic cholecystectomy. *Surg Endosc* 2008;22(7):1620–1624
  - 67 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. *Hepatology* 2009;50(1):291–308

- 68 Chapman R, Fevery J, Kalloo A, et al; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. *Hepatology* 2010;51(2):660–678
- 69 Farrell GC. *Drug-Induced Liver Disease*. Edinburgh, UK: Churchill Livingstone; 1994
- 70 Lewis JH, Kleiner DE. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, eds. *MacSween's Pathology of the Liver*. Philadelphia, PA: Elsevier; 2007
- 71 Kleiner DE, Chalasani NP, Lee WM, et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. *Hepatology* 2014;59(2):661–670
- 72 Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. *Aliment Pharmacol Ther* 2007;25(12):1411–1421
- 73 Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. *Liver Int* 2006;26(10):1225–1233
- 74 Hennes EM, Zeniya M, Czaja AJ, et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008;48(1):169–176
- 75 Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinkmanship and the point beyond salvation. *Liver Transpl* 2007;13(7):953–955
- 76 Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. *Liver Transpl* 2007;13(7):996–1003
- 77 Berends MA, van Oijen MG, Snoek J, et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. *Arch Dermatol* 2007;143(12):1515–1519
- 78 Rochon J, Protiva P, Seeff LB, et al; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. *Hepatology* 2008;48(4):1175–1183
- 79 Rockey DC, Seeff LB, Rochon J, et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. *Hepatology* 2010;51(6):2117–2126
- 80 Fontana RJ, Watkins PB, Bonkovsky HL, et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. *Drug Saf* 2009;32(1):55–68
- 81 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. *Hepatology* 2001;33(1):308–310
- 82 Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. *Gut* 1999;44(5):731–735
- 83 Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. *J Hepatol* 2009;50(3):511–517
- 84 Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology* 2014;56; Mar 26 [Epub ahead of print]